Heparin lock flush and Metastases to bone - a phase IV clinical study of FDA data
Metastases to bone is reported only by a few people who take Heparin Lock Flush.
The phase IV clinical study analyzes which people take Heparin lock flush and have Metastases to bone. It is created by eHealthMe based on reports of 616 people who have side effects while taking Heparin lock flush from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
616 people reported to have side effects when taking Heparin lock flush.
Among them, 2 people (0.32%) have Metastases to bone.
What is Heparin lock flush?
Heparin lock flush has active ingredients of heparin sodium. eHealthMe is studying from 642 Heparin lock flush users for its effectiveness, alternative drugs and more.
What is Metastases to bone?
Metastases to bone (cancer spreads to bone) is found to be associated with 1,578 drugs and 840 conditions by eHealthMe.
Number of Heparin lock flush and Metastases to bone reports submitted per year:
Gender of people who have Metastases to bone when taking Heparin lock flush *:
- female: 50 %
- male: 50 %
Age of people who have Metastases to bone when taking Heparin lock flush *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 50 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 50 %
Common drugs people take besides Heparin lock flush *:
- Zometa: 2 people, 100.00%
- Carboplatin: 2 people, 100.00%
- Fosamax: 2 people, 100.00%
- Zofran: 2 people, 100.00%
- Effexor: 2 people, 100.00%
- Duoneb: 2 people, 100.00%
- Ditropan: 2 people, 100.00%
- Dilantin: 2 people, 100.00%
- Dexamethasone: 2 people, 100.00%
- Demerol: 2 people, 100.00%
Common side effects people have besides Metastases to bone *:
- Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 2 people, 100.00%
- Breast Lump (localized swelling that feels different from the surrounding breast tissue): 2 people, 100.00%
- Haemoglobin Decreased: 2 people, 100.00%
- Headache (pain in head): 2 people, 100.00%
- Hepatic Cyst: 2 people, 100.00%
- Hepatic Mass: 2 people, 100.00%
- Atelectasis (partial or complete collapse of the lung): 2 people, 100.00%
- High Blood Pressure: 2 people, 100.00%
- Asthma: 2 people, 100.00%
- Hot Flush (sudden feelings of heat): 2 people, 100.00%
Common conditions people have *:
- Stress And Anxiety: 2 people, 100.00%
- Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 50.00%
* Approximation only. Some reports may have incomplete information.
Do you take Heparin lock flush and have Metastases to bone?Check whether Metastases to bone is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Metastases to bone and when was it recovered:
Expand to all the drugs that have ingredients of heparin sodium:
Alternative drugs to, pros and cons of Heparin lock flush:
- Heparin lock flush (642 reports)
Metastases to bone treatments and more:
- Metastases to bone (45,158 reports)
COVID vaccines that are related to Metastases to bone:
- Metastases to bone in Moderna COVID Vaccine
- Metastases to bone in Pfizer BioNTech Covid Vaccine
- Metastases to bone in Johnson and Johnson Covid Vaccine
Common drugs associated with Metastases to bone:
All the drugs that are associated with Metastases to bone:
- Metastases to bone (1,578 drugs)
Common conditions associated with Metastases to bone:
All the conditions that are associated with Metastases to bone:
- Metastases to bone (840 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on heparin sodium (the active ingredients of Heparin lock flush) and Heparin lock flush (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Aspirin and Emotional Distress - 2 seconds ago
- Diflunisal and Urticaria Aggravated - 3 seconds ago
- Deferasirox and Diflucan drug interaction - 4 seconds ago
- Beconase Aq and Simvastatin drug interaction - 6 seconds ago
- Aspirin and Staphylococcal Sepsis - 7 seconds ago
- Maxzide and Rib Fracture - 9 seconds ago
- Zerit and Abortion Missed - 10 seconds ago
- Dyazide and Flatulence - 10 seconds ago
- Uceris and Lomotil drug interaction - 17 seconds ago
- Singulair and Varenicline Tartrate drug interaction - 23 seconds ago